Teva Pharmaceutical Industries Limited (FRA:TEV)
Germany · Delayed Price · Currency is EUR | Market Cap | 34.05B +107.9% |
| Revenue (ttm) | 15.05B +4.4% |
| Net Income | 1.36B |
| EPS | 1.16 |
| Shares Out | n/a |
| PE Ratio | 25.08 |
| Forward PE | 14.48 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 290 |
| Average Volume | 1,266 |
| Open | 28.80 |
| Previous Close | 29.00 |
| Day's Range | 28.80 - 29.00 |
| 52-Week Range | 12.90 - 31.60 |
| Beta | n/a |
| RSI | 52.25 |
| Earnings Date | Apr 29, 2026 |
About FRA:TEV
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com... [Read more]
News
Fitch Upgrades Teva to Investment Grade Amid Pivot to Growth Execution
TEL AVIV, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Fitch Ratings Agency (“Fitch”) has raised the Company's corporate cred...
Teva Reports Gap In Tardive Dyskinesia Diagnosis Among Patients With Mood Disorders
(RTTNews) - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA) on Monday announced new real-world data from the IMPACT-TD Registry showing a significant gap in diagno...
Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread Impact
PARSIPPANY, N.J. and TEL AVIV, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data fr...
Larry Robbins' Strategic Moves: Significant Reduction in Teva Pharmaceutical Industries Ltd
Larry Robbins' Strategic Moves: Significant Reduction in Teva Pharmaceutical Industries Ltd
Teva Stock Is at Its Highest Level in Nearly a Decade. Here's Why It Could Soar Even More.
Teva is pivoting from generic-drug maker to major pharmaceutical company. Even after more than doubling in price over the past year, shares have more room to run, thanks to the company's robust pipeli...
Teva put volume heavy and directionally bearish
Bearish flow noted in Teva (TEVA) with 9,316 puts trading, or 8x expected. Most active are Jun-26 30 puts and Jun-26 37 calls, with total volume in those strikes near…
Wall Street Thinks Teva Stock Still Has Room to Run After Soaring Over 100%. Here's Why Analysts Are Right.
Teva's turnaround is real -- and may not be over.
Teva Pharmaceutical Industries Ltd at Bank of America Global Healthcare Conference Transcript
Teva Pharmaceutical Industries Ltd at Bank of America Global Healthcare Conference Transcript
Teva Pharmaceutical Industries Transcript: Bank of America Global Healthcare Conference 2026
Accelerated development of five late-stage programs is enabled by strategic funding deals, aiming for annual launches through 2027. Key assets include anti-IL-15 for vitiligo, TL1A for IBD, and an oral alpha-synuclein agent, with robust device and generics strategies supporting growth.
Insider Sell: Amir Weiss Sells Shares of Teva Pharmaceutical Industries Ltd (TEVA)
Insider Sell: Amir Weiss Sells Shares of Teva Pharmaceutical Industries Ltd (TEVA)
Teva price target raised to $40 from $38 at Barclays
Barclays raised the firm’s price target on Teva (TEVA) to $40 from $38 and keeps an Overweight rating on the shares. Published first on TheFly – the ultimate source for
Royalty Pharma Reports Q1 2026 Results: Full Earnings Call Transcript
Royalty Pharma (NASDAQ: RPRX) held its first-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For rea...
Insider Sell Alert: Mark Sabag Sells 144,180 Shares of Teva Pharmaceutical Industries Ltd (TEVA)
Insider Sell Alert: Mark Sabag Sells 144,180 Shares of Teva Pharmaceutical Industries Ltd (TEVA)
Teva to Present at the BofA Securities Health Care Conference
PARSIPPANY, N.J., and TEL AVIV, Israel, May 04, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Eric Hughes, Teva's EVP of Global R&D & Chief Me...
TEVA Maintained by JP Morgan -- Price Target Raised to $40.00
TEVA Maintained by JP Morgan -- Price Target Raised to $40.00
TEVA Maintained by UBS -- Price Target Raised to $42.00
TEVA Maintained by UBS -- Price Target Raised to $42.00
TEVA Reiterated by Piper Sandler -- Price Target Raised to $42.00
TEVA Reiterated by Piper Sandler -- Price Target Raised to $42.00
TEVA Maintains Buy Rating with Truist Securities -- Price Target Raised to $45
TEVA Maintains Buy Rating with Truist Securities -- Price Target Raised to $45
Teva price target raised to $50 from $45 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Teva (TEVA) to $50 from $45 and keeps a Buy rating on the shares. Teva delivered encouraging results, with strong outperformance in
Teva price target raised to $40 from $35 at JPMorgan
JPMorgan raised the firm’s price target on Teva (TEVA) to $40 from $35 and keeps an Overweight rating on the shares. Published first on TheFly – the ultimate source for
Teva price target raised to $42 from $41 at Piper Sandler
Piper Sandler raised the firm’s price target on Teva (TEVA) to $42 from $41 and keeps an Overweight rating on the shares following quarterly results. The firm notes Teva continues
Teva's 2025 Healthy Future Report Highlights Environmental and Access to Medicines Progress, Including Meeting All Sustainability-Linked Bond Targets
TEL AVIV, Israel, April 30, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today published its 2025 Healthy Future Report, outlining performance against its sustain...
Teva price target raised to $42 from $36 at UBS
UBS raised the firm’s price target on Teva (TEVA) to $42 from $36 and keeps a Buy rating on the shares. Teva reported Q1 results that reinforce improving confidence in
Blackstone's $400 Million Bet on Teva: What Does the Smart Money Know That Most Investors Don't?
A significant financing deal with Blackstone underscores that the Teva of today isn't the Teva of the past.
Teva Pharmaceutical Industries Ltd (TEVA) Q1 2026 Earnings Call Highlights: Strong Innovative ...
Teva Pharmaceutical Industries Ltd (TEVA) Q1 2026 Earnings Call Highlights: Strong Innovative Portfolio Growth Amid Revenue Challenges